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Abstract
Although the C-statistic is widely used for evaluating the performance of diagnostic
tests, its limitations for evaluating the predictive performance of biomarker panels have
been widely discussed. The increment in C obtained by adding a new biomarker to a
predictive model has no direct interpretation, and the relevance of the C-statistic to risk
stratification is not obvious. This paper proposes that the C-statistic should be replaced
by the expected information for discriminating between cases and noncases (expected
weight of evidence, denoted as Λ), and that the strength of evidence favouring one
model over another should be evaluated by cross-validation as the difference in test
log-likelihoods. Contributions of independent variables to predictive performance are
additive on the scale of Λ. Where the effective number of independent predictors is
large, the value of Λ is sufficient to characterize fully how the predictor will stratify
risk in a population with given prior probability of disease, and the C-statistic can
be interpreted as a mapping of Λ to the interval from 0.5 to 1. Even where this
asymptotic relationship does not hold, there is a one-to-one mapping between the
distributions in cases and noncases of the weight of evidence favouring case over
noncase status, and the quantiles of these distributions can be used to calculate how the
predictor will stratify risk. This proposed approach to reporting predictive performance
is demonstrated by analysis of a dataset on the contribution of microbiome profile to
diagnosis of colorectal cancer.
Keywords
diagnostic test, biomarkers, risk stratification, precision medicine, weight of evidence,
cross-validation, C-statistic, Kullback-Leibler divergence, relative entropy, Bayesian
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Introduction 1
The advent of platforms that can measure panels of hundreds or thousands of 2
biomarkers presents new opportunities for developing diagnostic tests not only to 3
detect disease, but to stratify people by risk and to predict response to therapy. It 4
is widely expected that this will lead to a new era of “precision medicine” (1). 5
The growth of research in this field has highlighted the limitations of current 6
methods for evaluating the predictive performance of biomarker panels. There is 7
no consensus on how to evaluate the incremental contribution of a biomarker 8
panel to predictions based on clinical variables, and it is not clear how to use 9
summary measures of predictive performance to evaluate the usefulness of a 10
biomarker panel as a risk stratifier. 11
This paper is organized as follows. First, the limitations of current methods for 12
quantifying performance of a diagnostic test are briefly reviewed. Next, the 13
rationale for an alternative approach based on information theory and Bayesian 14
inference is presented, and methods for calculating it are described. The proposed 15
approach is demonstrated by applying it to a study that used a high-dimensional 16
biomarker panel to distinguish cases and controls. The discussion section 17
examines the relevance of other approaches to quantifying the information 18
conveyed by an experiment or test, and recent guidelines for reporting predictive 19
performance of diagnostic tests. 20
Limitations of current methods for quantifying performance of a 21
classifier 22
The area under the receiver operating characteristic (ROC) curve or C-statistic is 23
the most widely-used measure for evaluating the performance of a score in 24
predicting a binary outcome. For simplicity, I denote the outcome as “disease”, 25
and the outcome categories as “case” and “control” though the argument applies 26
more generally. Among the advantages of the C-statistic are that it does not 27
require calibration and that it does not depend on the prevalence of disease, so 28
that in principle an estimate obtained in a case-control study can be generalized 29
to a clinical setting. With some additional assumptions, use of the C-statistic to 30
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evaluate the ranking of cases and controls is a proper scoring rule (2). This means 31
that the assessed predictive performance is maximized by reporting the 32
probabilities (or ranks) assigned by the forecaster. However the C-statistic also 33
has serious limitations that have been widely discussed. 34
• It is not obvious what the C-statistic, defined as the probability of correctly 35
classifying a case-control pair, tells us about the usefulness of a score for 36
risk stratification in the population. 37
• The increment in the C-statistic obtained by adding new variables has no 38
obvious interpretation. When a new predictor such as a biomarker is added 39
to a baseline predictive model, the increment in C-statistic will depend 40
upon what covariates have been included in the baseline model and on the 41
extent to which these covariates have been matched between cases and 42
controls (3; 4), even if the new predictor is uncorrelated with these 43
covariates (5). The most efficient design in which to discover new 44
biomarkers is a nested case-control study in which stored samples from 45
cases are compared with controls matched for clinical covariates. When the 46
predictive performance of a biomarker discovered in such a study is 47
evaluated in a cohort study without matching for covariates, the increment 48
in C-statistic obtained by adding the biomarker to this baseline model will 49
be lower for reasons explained below. It is possible to work around this by 50
standardizing the calculation of the ROC curve for covariates (6; 7), but 51
this further complicates analysis and interpretation. 52
• The small increments in C-statistic that can be achieved by adding new 53
variables to an baseline model that has a C-statistic of 0.9 or above have led 54
to a mistaken belief that no useful increment in predictive performance can 55
be obtained. “Researchers have observed that ∆AUC depends on the 56
performance of the underlying clinical model. For example, good clinical 57
models are harder to improve on, even with markers that have shown strong 58
association” (8). Others have suggested that the problem lies in the 59
interpretability of the C-statistic: “for models containing standard risk 60
factors and possessing reasonably good discrimination, very large 61
‘independent’ associations of the new marker with the outcome are required 62
to result in a meaningfully larger AUC” (9) 63
To supplement reporting of the C-statistic and the ROC curve, additional 64
descriptors have been suggested. The cumulative distribution function F of the 65
score values in controls can be estimated, and the distribution of the values 66
returned by applying F to the score values in cases can be plotted as density of 67
“percentile values” (10). The average of these values is equivalent to the 68
C-statistic. To assess how the score will perform in a target population, the 69
quantiles of predictive probability in that population can be plotted as a 70
“predictiveness curve” (11); this however does not quantify predictive performance 71
independently of the population in which the classifier is used. 72
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To evaluate the incremental contribution of a new biomarker to prediction, 73
alternative indices have been proposed, based on the proportion of individuals 74
who are reclassified when the biomarker is added to the model: these include 75
“integrated discrimination improvement” and “net reclassification index” (9). 76
However these indices are not proper scoring rules (12); this means that adding a 77
biomarker to the predictive model can apparently “improve” such an index even 78
when that biomarker contains no predictive information (13; 14). The authors of 79
a widely-quoted set of guidelines on reporting of multivariate models for diagnosis 80
noted that “Identifying suitable measures for quantifying the incremental value of 81
adding a predictor to an existing prediction model remains an active research 82
area” (15). 83
Relation of C-statistic to expected information for 84
discrimination 85
In a Bayesian framework, the weight of evidence favouring one hypothesis over 86
another is the logarithm of the ratio of the likelihoods of the hypotheses given the 87
data (16). This ratio of likelihoods of hypotheses is sometimes called the Bayes 88
factor to distinguish it from the likelihood ratio tests used in classical statistics, 89
which compare likelihoods at different values of a model parameter. The weight of 90
evidence is not a scoring rule for comparison of classifiers: rather it is the 91
difference between the logarithmic scores for the two hypotheses being compared 92
(17). The C-statistic, defined as the probability of correctly classifying a 93
case-control pair, is the probability that the weight of evidence in favour of the 94
correct assignment of case-control status to this pair is greater than zero. We can 95
calculate C, and also characterize the usefulness of the predictor for risk 96
stratification, if we know the sampling distributions of the weight of evidence 97
favouring case over control status in cases and controls. 98
Good and Toulmin (1968) (18) showed that for two alternative hypotheses H1 99
and H0 the characteristic functions ϕ1 (t), ϕ0 (t) of the distributions of the weight 100
of evidence W1/0 favouring H1 over H0 when H1 is true and when H0 is true are 101
related by the identity ϕ1 (t+ i) = ϕ0 (t), where i is the imaginary unit. This 102
identity can be stated in an alternative form as 103
exp
(−W1/0)p1 (W1/0) = p0 (W1/0), where p1 (W1/0) and p0 (W1/0) are the 104
densities of W1/0 when H1 is true and when H0 is true respectively. This result 105
can be obtained simply by noting that at any value of W the ratio 106
p1
(
W1/0
)
/p0
(
W1/0
)
is the Bayes factor exp
(
W1/0
)
favouring H1 over H0. This 107
identity generalizes two results attributed to Turing (16):- 108
1. If the sampling distribution of the weight of evidence favouring a hypothesis 109
H1 over a hypothesis H0 is Gaussian with mean Λ when H1 is true, its 110
sampling distribution when H0 is true is Gaussian with mean −Λ, and both 111
distributions have variance 2Λ (when natural logarithms are used). 112
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2. The expected Bayes factor in favour of a wrong hypothesis is 1 (because 113
exp
(−W1/0)p1 (W1/0) integrates to 1). The practical implications of this 114
result are examined in the Discussion section. 115
The sampling distribution of the weight of evidence is asymptotically Gaussian if 116
there are many explanatory variables and their independent contributions are 117
small (18). If this asymptotic distribution holds, the relation between the 118
C-statistic and the expected weight of evidence Λ favouring true over false status 119
is given by C = 1− Φ
(
−√Λ
)
or Λ =
[
Φ−1 (C)
]2 where Φ (·) is the standard 120
Gaussian cumulative distribution function (19). In this situation the C-statistic 121
can be interpreted as a mapping of Λ (which can take values from 0 to infinity), 122
to the interval from 0.5 to 1 as shown in Figure 1. A special case of this relation 123
has been noted previously (20): with a single explanatory variable for which the 124
class-conditional distributions in cases and controls are Gaussian with the same 125
variance, Λ = 12β2 and C = 1− Φ
(−|β|/√2), where β is the standardized logistic 126
regression coefficient of the outcome on the explanatory variable. More generally 127
if the class-conditional distributions of the explanatory variables in cases and 128
controls are Gaussian with the same covariance matrix, the sampling distribution 129
of the weight of evidence favouring true over false status is Gaussian and the 130
relation between C and Λ holds exactly (19). 131
The asymptotic relation between C and the expected weight of evidence Λ 132
suggests that we might use Λ to report predictive performance. The statistic Λ 133
has various alternative names: the expected information for discriminating 134
between cases and controls; the Kullback-Leibler (KL) divergence from the 135
class-conditional distribution Q of the predictors under incorrect case-control 136
assignment to their distribution P under correct assignment; or the relative 137
entropy of P with respect to Q. As Λ is a KL divergence, it can take only 138
non-negative values. The expected information for discrimination has a more 139
intuitive interpretation than the C-statistic, because the mathematical definition 140
of information as reduction in entropy corresponds closely to intuitive ideas of 141
information (21). Improbable or surprising observations convey more information 142
than unexceptional observations. 143
To facilitate intuitive interpretation of Λ, we can use logarithms to base 2, so that 144
the expected information is expressed in bits. Figure 1 shows that a C-statistic of 145
0.7, sometimes cited as the threshold for “modest” predictive performance(22), is 146
asymptotically equivalent to only 0.4 bits on the scale of Λ. More appropriate 147
cutoffs for moderate and good prediction would be one bit and three bits, for 148
which the asymptotically equivalent C values are respectively 0.8 and 0.925. 149
Using Figure 1 we can explain how increments in the C-statistic may be 150
misleading when used to evaluate the incremental contribution of a biomarker 151
panel to predictive performance. For instance, in a case-control study where cases 152
and controls have been matched for covariates so that the baseline model has a 153
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C-statistic of 0.5, adding a biomarker that contributes one bit of information for 154
discrimination would increase the asymptotically equivalent C-statistic from 0.5 155
to 0.8. When the same biomarker is evaluated in an unmatched cohort study in 156
which the covariates contribute two bits of information, the baseline model will 157
have a C-statistic of 0.88 and adding the biomarker will increase this only to 158
0.925. Whether or not the asymptotic relation between C and the expected 159
weight of evidence Λ holds, contributions of independent predictors are additive 160
on the scale of Λ; this supports using Λ instead of C to quantify predictive 161
performance and the incremental contribution of additional biomarkers. In human 162
genetics, the strength of the genetic effect on a disease is often quantified as the 163
sibling recurrence risk ratio λS , defined as the ratio of disease risk in a sibling of 164
an affected individual to average risk in the population. Under a polygenic model 165
in which effects are additive on a logistic scale, Λ = log λS (23). 166
Evaluating the distributions of weight of evidence 167
To evaluate the performance of a predictive model, and the strength of evidence 168
favouring one model over another over another, we require a test dataset with the 169
observed case-control status yi (coded as control = 0, case = 1) of the ith 170
individual, the predicted probability pi of disease in this individual generated by 171
the model, and the prior probability of disease P given by the observed frequency 172
of disease in the training dataset. This test dataset can be formed either by a 173
single test/training split or by concatenating the N disjoint test folds used for 174
N -fold cross-validation. Although the asymptotic properties discussed below are 175
for leave-one-out cross-validation, it is not usually necessary in large datasets to 176
proceed to the limit of leave-one-out; it is sufficient to start with N = 10 for 177
N -fold cross-validation and to double N until the results do not change 178
appreciably. For survival modelling where failure times are directly observed, the 179
dataset can be rearranged with one observation per person-time interval, and the 180
average taken over person-time intervals. 181
The weight of evidence wi favouring correct over incorrect case-control assignment 182
in the ith individual is calculated using Bayes theorem, by subtracting the log 183
prior odds from the log posterior odds 184
wi = (2yi − 1)
(
log pi1−pi − log P1−P
)
185
Λ is estimated as the average of wi over all cases and controls in the test dataset. 186
The distributions of weight of evidence in cases and controls can then be 187
examined. If these distributions have the asymptotic form derived by Turing, the 188
expectation Λ contains all the information we need to compute quantiles of weight 189
of evidence favouring case over control status in cases and controls. Otherwise to 190
compute these quantiles we have to estimate these distributions from the data. 191
For these estimated distributions to be consistent, they should be constrained so 192
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that at each value of W the ratio of density in cases to density in controls is 193
exp (W ). The densities in cases and controls can be obtained by multiplying the 194
geometric mean of these densities (as a function of W ) by exp
( 1
2W
)
and 195
exp
(− 12W ) respectively. The problem of estimating a consistent pair of densities 196
can thus be reduced to the problem of estimating this geometric mean function. A 197
workable procedure for this is described below, where f0 (W ) and f1 (W ) denote 198
estimated densities of the weight of evidence W favouring case over control status 199
in cases and controls respectively. 200
1. Fit smoothed kernel densities f1 (W ), f0 (W ) to the values of W in the case 201
and control samples respectively over a grid of values of W . 202
2. Estimate the geometric mean of the densities in cases and controls as a 203
function of W as a weighted average of f1 (W ) exp
(− 12W ) and 204
f0 (W ) exp
( 1
2W
)
. Weights for cases and controls are proportional to the 205
expected numbers of cases and controls at each value of W : number of cases 206
× exp ( 12W ), number of controls × exp (− 12W ) respectively. This reduces to 207
evaluating the arithmetic mean of the case and control densities as a 208
function of W . 209
3. Calculate the adjusted densities g1 (W ), g0 (W ) in cases and controls by 210
multiplying this estimated geometric mean function by exp
( 1
2W
)
and 211
exp
( 1
2W
)
respectively. 212
For the ratio g1 (W ) /g0 (W ) to be exactly exp (W ), these adjusted densities 213
must have the same normalizing constant. This requires a slight reweighting 214
of the unadjusted densities f1 (W ) and f0 (W ). The weighting function is 215
exp
(
±θ (wi − w¯)2
)
where w¯ is the sample mean of the weight of evidence 216
and the sign before θ is positive in cases and negative in controls. The 217
optimal value of θ is determined by using an optimization algorithm such as 218
the optim function in the R package to minimize an objective function 219
defined as the absolute value of the logarithm of the ratio of the two 220
normalizing constants. The optimal value of θ is usually very close to zero - 221
in other words, only very slight reweighting is required to ensure that the 222
adjusted densities have the same normalizing constant. 223
Relation of the distributions of weight of evidence to the 224
receiver operating characteristic curve 225
Johnson (24) noted a simple relationship between the distributions of weight of 226
evidence W favouring case over control status in cases and controls and the ROC 227
curve generated from these distributions. If the quantiles of W in controls and 228
cases are q0 and q1 respectively, the sensitivity is (1− q1) and the specificity is q0 229
and the ROC is the curve obtained by plotting (1− q1) as a function of (1− q0). 230
The gradient of this function is 231
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dq1
dq0
= dq1/dW
dq0/dW
= g1 (W )
g0 (W )
= exp (W )
As q0 (W ) increases with W , it follows that the gradient of this model-based ROC 232
curve is a monotonic decreasing function of (1− q0), unlike the crude ROC curve 233
calculated from ranking the scores of cases and controls. This model-based ROC 234
curve generated from the adjusted distributions of W in cases and controls 235
contains the same information as a plot of the distributions, but is more difficult 236
to use to quantify how the score will behave as a risk stratifier because the 237
likelihood ratio cannot be read off a logarithmic scale on the axis but instead is 238
represented as the gradient of the curve. A plot of the adjusted cumulative 239
distributions of W in cases and controls is the most useful graphical 240
representation of how the classifier can be used as a risk stratifier. 241
Evaluating the strength of evidence that adding one or more 242
biomarkers improves prediction 243
To evaluate the strength of evidence that adding a biomarker or a panel of 244
biomarkers improves prediction, we can evaluate the difference in log-likelihoods 245
of the corresponding models given the test data. The log-likelihood of the model 246
given test data on the ith individual is 247
logL = ∑i [yi log pi + (1− yi) log (1− pi)] 248
Model comparison based on the test log-likelihood is equivalent to using the 249
logarithmic scoring rule, which is strictly proper. In a Bayesian framework, the 250
difference in log-likelihoods of models can be interpreted directly as the weight of 251
evidence favouring one model over another, without having to evaluate its 252
sampling distribution. It is possible to construct a test based on the distribution 253
of the C-statistic over hypothetical repeated sampling of test datasets (25), but 254
this is not the same as a classical p-value based on the distribution of the test 255
statistic over hypothetical repeated sampling of training datasets (26). It is of 256
interest to compare the relationship of these classical tests to inference based on 257
test log-likelihoods. For leave-one-out cross-validation, the difference in test 258
log-likelihoods of models is asymptotically equivalent to the difference in the 259
values of the Akaike Information Criterion (27) (evaluated in natural log units 260
rather than deviance units) on the training data, and 2 (∆ logL+ k) has 261
asymptotically a chi-square distribution with k degrees of freedom. where ∆ logL 262
is the difference in test log-likelihoods (in natural log units) of models with and 263
without the extra biomarkers, and k is the effective number of extra parameters. 264
Thus for a single extra variable, a test log-likelihood ratio of 20, which might be 265
considered moderately strong evidence that a biomarker improves prediction, is 266
asymptotically equivalent to a p-value of 0.0047 on the training dataset. 267
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Example: incremental contribution of microbiome profile to 268
detection of colorectal cancer 269
To demonstrate this approach to reporting the incremental contribution of a 270
biomarker panel to prediction, these methods were applied to analysis of a 271
publicly available dataset from a study of detection of colorectal cancer in 272
symptomatic individuals, using fecal microbiome profile in addition to the 273
standard fecal immunochemical test (FIT) for blood (28). The dataset consisted 274
of quantitative FIT results and microbiome profiles on 101 cases of cancer and 141 275
controls (after excluding those with adenoma). For the predictive modelling, the 276
number of variables in the microbiome profiles was restricted to 201 operational 277
taxonomic units (OTUs) that had nonzero values in at least 20% of individuals. 278
The Bayesian program Stan (29) was used to generate the posterior distribution 279
of predictive probabilities from two alternative logistic regression models: a 280
baseline model with FIT only and an uninformative prior on the effect parameter, 281
and a model with FIT plus the microbiome markers, with a hierarchical shrinkage 282
prior on the microbiome variables that allows the algorithm to learn that most 283
effect sizes are near zero (30). The prediction of colorectal cancer in test data was 284
evaluated by 40-fold cross-validation, with predictive probabilities evaluated as 285
the average of 2000 posterior samples on each test fold. The densities were 286
adjusted as described above to make them consistent, with reweighting parameter 287
θ = 0.00018. 288
Table 1 compares the model with FIT + microbiome profile to the model with 289
FIT only. Including the microbiome profile increases the C-statistic from 0.892 to 290
0.932. This result might be misinterpreted as showing that the microbiome profile 291
makes only a small incremental contribution to prediction when compared with a 292
baseline model using FIT only. However the expected information for 293
discrimination is approximately doubled from 3 to 6.5 bits when the microbiome 294
profile is added to the model. The strength of evidence that this improves 295
prediction can be evaluated as the difference in test log-likelihood, which is 60.2 296
bits. 297
In this example where one variable(FIT) accounts for half the expected 298
information and the class-conditional distributions of this variable are far from 299
Gaussian (most FIT values in controls are zero), we would not necessarily expect 300
the weight of evidence to follow its asymptotic Gaussian distribution. Figure 2 301
shows the unadjusted estimates of the densities in cases and controls of the weight 302
of evidence favouring case over control status are skewed, together with the 303
densities adjusted as described above to make them consistent. The main effect of 304
this adjustment is to shrink the left tail of the density in cases and the right tail 305
of the density in cases. Thus, for instance at W = −6 bits where the true 306
case/control density ratio is 1:64 and the unadjusted ratio is about 1:7, 307
adjustment shrinks the density in cases and increases the density in controls 308
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slightly. The model-based estimates of Λ and C, based on the adjusted densities, 309
are higher than the crude estimates. 310
Figure 3 shows the adjusted cumulative frequency distributions. These can be 311
used to evaluate how a combined test based on FIT and microbiome profile could 312
be used for risk stratification in a clinical setting (for illustrative purposes only, 313
not as a policy recommendation). For instance suppose that in a setting in which 314
the prior probability of colorectal cancer in symptomatic individuals referred from 315
primary care is 5% (prior odds 1:19), a threshold of at least 1% risk of cancer 316
(posterior odds 1:99) has been set as the criterion for further investigation by 317
colonoscopy. From the adjusted cumulative frequency distributions we can 318
estimate that using this risk threshold (weight of evidence favouring case over 319
noncase status log2 19/99 = -2.38 bits) with a combined test based on FIT and 320
microbiome profile would exclude 2% of cancer cases and 88% of noncases as 321
having posterior probability of cancer less than 1%. 322
This study illustrates also how the the projection predictive method (31; 32) can 323
be used to select the most predictive variables. After evaluating predictive 324
performance by cross-validation, 2000 posterior samples of the fitted values of the 325
linear predictor were generated from a model with FIT + microbiome profile 326
fitted to the full data and forward selection was performed using the projection 327
predictive method. The increment in predictive information contributed by each 328
additional biomarker was evaluated as the reduction in KL divergence of 329
full-model fitted values from their projection on to the subspace of microbiome 330
variables selected. Figure 4 shows that the predictive information in the 331
microbiome profile is contributed by many variables of small effect. 332
Discussion 333
Although the expected information for discrimination (expected weight of 334
evidence) is a natural measure of the information content of a test or 335
experimental design that contrasts two alternative hypotheses, it has not been 336
widely used for this purpose in biostatistics, except in genetic linkage analysis 337
during the pre-genome era where the weight of evidence (lod score) was used to 338
quantify support for linkage, and the expectation of the lod score (ELOD) was the 339
accepted measure of the information content of a study design (33). Lee (1999) 340
(34) suggested reporting the expected information for discrimination in cases and 341
controls separately to quantify the performance of a test score, but assumed that 342
likelihood ratios would be evaluated by tabulating frequencies of scores grouped 343
into ordinal categories, rather than by using the predictive probabilities output by 344
the classifier to evaluate the likelihood ratio as the ratio of posterior odds to prior 345
odds. In practice, estimates of probability ratios based on grouping scores into 346
bins would be unstable: if only an uncalibrated test score were available, it would 347
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be better to fit a model (such as a logistic regression) that outputs predictive 348
probabilities before computing the expected weight of evidence. 349
An alternative approach to quantifying the information content of an experiment 350
or test is to calculate the expected gain of information on the outcome (35). In 351
the context of a diagnostic test, this would be the KL divergence from the prior 352
to the posterior distribution of case-control status, rather than the expected 353
information for discrimination which is the KL divergence from the distribution of 354
the predictors given incorrect assignment to their distribution given correct 355
assignment of case-control status(36). Unlike the expected information for 356
discrimination, the expected gain of information about the outcome is not 357
additive for independent biomarkers, and depends on the prevalence of disease so 358
cannot be generalized from one setting to another. 359
A key requirement for quantifying predictive performance is that it should be 360
evaluated not on the training data used to learn the model but on test data not 361
seen before. Unless a very large dataset is available in which a single test / 362
training split provides both a training dataset adequate to learn an optimal 363
predictive model and a test dataset large enough to estimate predictive 364
performance accurately, the most efficient way to evaluate performance will be 365
through cross-validation. Without internal validation (through cross-validation or 366
a single test/train split), it is not possible to evaluate whether poor performance 367
on a test dataset is attributable to lack of generalizability or to lack of predictive 368
information in the original dataset. Several groups have recently produced 369
guidelines for reporting the evaluation of risk predictors or diagnostics using 370
biomarkers: REMARK (37), GRIPS (38), STARD (39), and TRIPOD (15), 371
Although evaluation of predictive performance by cross-validation is mentioned in 372
supplementary materials, the summary recommendations and checklists do not 373
emphasize this critical point. Even where studies report using cross-validation to 374
evaluate predictive performance, it is not always clear that the test data have not 375
been used at some earlier stage to learn the model. A common malpractice is to 376
use the full dataset for variable selection, before the split into test/training folds 377
(40). The wider adoption of reproducible research requirements (41), may make it 378
easier for readers to determine whether correct practice was followed. 379
As long as the learning algorithm generates predictive probabilities, the expected 380
information for discrimination can be evaluated just as easily on “black-box” 381
predictors such as kernel-based learning algorithms as on simple logistic regression 382
models. However unlike the C-statistic which depends only upon how the 383
predictor ranks cases and controls, the expected information for discrimination 384
depends on calibrating the predictor so that the predictive probabilities equate to 385
the observed frequencies of cases at each level of the predictors in the test dataset. 386
For a linear model with likelihood in the exponential family, maximizing the 387
likelihood guarantees that the model is correctly calibrated to the training data 388
(21). Thus where the test and test and training datasets are random subsamples 389
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of the original dataset, formed either by a single test/training split or by 390
cross-validation, calibration is unlikely to be a problem. If a predictor is to be 391
evaluated in a different setting to that in which it was developed, it will usually 392
be necessary to recalibrate it by adding an intercept term on the scale of log odds 393
so as to equate the observed and predicted number of cases. 394
The expected weight of evidence can be given an intuitive interpretation: for 395
instance an expected weight of evidence of 3 bits implies that a “typical” result 396
would be for the posterior odds in favour of the true case-control status to be 397
eight times the prior odds. For a predictor that is based on a large number of 398
independent biomarkers of small effect, the asymptotic distribution derived by 399
Turing will hold and the expected information for discrimination will be enough 400
to characterize fully the distributions of the weight of evidence in cases and 401
controls. Means and variances of the estimated distributions of the weight of 402
evidence in cases and controls, together with a plot of these distributions, should 403
be reported to allow the reader to determine whether this asymptotic distribution 404
holds. Even where it does not hold, the other advantages of using the expected 405
weight of evidence - additivity of effects of independent predictors, and its 406
intuitive interpretation - support its use as a summary measure of predictive 407
performance. However to evaluate how the predictor will perform as a risk 408
stratifier, the reader will need the distributions in cases and controls if these 409
distributions do not have their asymptotic form. A plot of these distributions is 410
thus more useful than a conventional plot of the ROC curve. 411
Visualizing these distributions shows something not widely appreciated: that 412
however good the classifier, the distribution of the weight of evidence in favour of 413
the wrong hypothesis has a tail that extends well to the right of zero. This is a 414
corollary of Turing’s result that the expectation of the Bayes factor in favour of 415
the wrong hypothesis is 1: the distribution of this Bayes factor becomes more 416
right-skewed as the expectation of the log Bayes factor (weight of evidence) 417
becomes more negative (16). A practical and disconcerting consequence is that if 418
a classifier has high performance, it will not often be wrong but when it is wrong 419
it may be wildly wrong, giving a high likelihood ratio in favour of the wrong 420
hypothesis. Thus if the weight of evidence has its asymptotic distribution, a 421
diagnostic test that has an expected weight of evidence of 4 bits (equivalent to 422
C-statistic of 0.95) will generate a likelihood ratio more than 8 to 1 in favour of 423
the wrong assignment of disease status in 2% of individuals tested. While this 424
may be acceptable for risk stratification, failure to appreciate the fallibility of the 425
multivariate in vitro diagnostic tests now coming into use could have serious 426
consequences in clinical practice. 427
Online resources 428
An R script to estimate the procedure described for estimating the distribution of 429
weights of evidence is available at http://www.homepages.ed.ac.uk/pmckeigu/ 430
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Figure 1. Asymptotic relationship of C-statistic to expected information for discrimination Λ
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Figure 2. Distributions in cases and controls of weights of evidence favouring case over
control status, from model combining FIT test with microbiome profile. Weights of evidence
were computed on test folds by 40-fold cross-validation. Unadjusted densities were smoothed
with a Gaussian kernel using bandwidth chosen by the Sheather-Jones algorithm. Adjusted
densities were calculated from the mean of the unadjusted case and control densities as
described in the text.
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Figure 3. Adjusted cumulative distributions in cases and controls of weight of evidence.
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Figure 4. Proportion of total predictive information in microbiome profile obtained by
forward selection of variables, using projective predictive method with posterior samples
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Model Crude C-
statistic
Crude Λ
(bits)
Adjusted
C-
statistic
Adjusted
Λ (bits)
∆ logL
(bits)
FIT only 0.892 3.0 0.930 3.0 0
FIT + micro-
biome
0.932 6.5 0.990 7.3 60.2
Table 1. Incremental contribution of microbiome profile to detection of colorectal cancer,
compared with baseline model using faecal immunochemical test (FIT) only
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